APA

Fizazi K., Carducci M., Smith M., Damião R., Brown J., Karsh L., Milecki P., Shore N., Rader M., Wang H., Jiang Q., Tadros S., Dansey R. & Goessl C. (20110323). Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. : Lancet (London, England).

Chicago

Fizazi Karim, Carducci Michael, Smith Matthew, Damião Ronaldo, Brown Janet, Karsh Lawrence, Milecki Piotr, Shore Neal, Rader Michael, Wang Huei, Jiang Qi, Tadros Sylvia, Dansey Roger and Goessl Carsten. 20110323. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. : Lancet (London, England).

Harvard

Fizazi K., Carducci M., Smith M., Damião R., Brown J., Karsh L., Milecki P., Shore N., Rader M., Wang H., Jiang Q., Tadros S., Dansey R. and Goessl C. (20110323). Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. : Lancet (London, England).

MLA

Fizazi Karim, Carducci Michael, Smith Matthew, Damião Ronaldo, Brown Janet, Karsh Lawrence, Milecki Piotr, Shore Neal, Rader Michael, Wang Huei, Jiang Qi, Tadros Sylvia, Dansey Roger and Goessl Carsten. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. : Lancet (London, England). 20110323.